Coherus Oncology (CHRS) Current Deferred Revenue (2013 - 2017)

Coherus Oncology has disclosed Current Deferred Revenue across 5 years of filings, most recently posting $669000.0 for Q1 2017.

• Current Deferred Revenue for Q1 2017 came in at $669000.0, down 98.65% year-over-year; the trailing twelve-month figure through Mar 2017 was $669000.0 (down 98.65% YoY), and the FY2016 annual result was $892000.0, down 98.2% from the prior year.
• Current Deferred Revenue came in at $669000.0 for Q1 2017 at Coherus Oncology, down from $892000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $61.3 million in Q2 2016 to a low of $162000.0 in Q1 2015.
• The 5-year median for Current Deferred Revenue is $22.8 million (2014), against an average of $22.0 million.
• Across the five-year window, Current Deferred Revenue surged 30537.65% in 2016 and plunged 98.65% in 2017, its largest moves.
• Coherus Oncology's Current Deferred Revenue stood at $14.3 million in 2013, then jumped by 59.63% to $22.8 million in 2014, then soared by 117.64% to $49.6 million in 2015, then tumbled by 98.2% to $892000.0 in 2016, then declined by 25.0% to $669000.0 in 2017.
• The last three Current Deferred Revenue figures came in at $669000.0 (Q1 2017), $892000.0 (Q4 2016), and $1.4 million (Q3 2016), per Business Quant data.